Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 361 AL 372

Metal ions, Alzheimer's disease and chelation therapy

Budimir A.

Acta Pharm. 2011 Mar;61(1):1-14. doi: 10.2478/v10007-011-0006-6.

Therapeutic intervention at cellular quality control systems in Alzheimer's and Parkinson's diseases

Arduino DM, Esteves AR, Silva DF, Martins-Branco D, Santos D, Pimentel DF, Cardoso SM.

Curr Pharm Des. 2011;17(31):3446-59. doi: 10.2174/138161211798072481.

Targeting HDACs: a promising therapy for Alzheimer's disease

Xu K, Dai XL, Huang HC, Jiang ZF.

Oxid Med Cell Longev. 2011;2011:143269. doi: 10.1155/2011/143269. Epub 2011 Sep 20.

Multimodal drugs and their future for Alzheimer's and Parkinson's disease

Van der Schyf CJ, Geldenhuys WJ.

Int Rev Neurobiol. 2011;100:107-25. doi: 10.1016/B978-0-12-386467-3.00006-6.

Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology

O'Brien JT, Burns A; BAP Dementia Consensus Group.

J Psychopharmacol. 2011 Aug;25(8):997-1019. doi: 10.1177/0269881110387547. Epub 2010 Nov 18.

Mechanisms mediating brain and cognitive reserve: experience-dependent neuroprotection and functional compensation in animal models of neurodegenerative diseases

Nithianantharajah J, Hannan AJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):331-9. doi: 10.1016/j.pnpbp.2010.10.026. Epub 2010 Nov 26.

Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Riederer P, Bartl J, Laux G, Grünblatt E.

Neurotox Res. 2011 Feb;19(2):253-65. doi: 10.1007/s12640-010-9203-1. Epub 2010 Jun 15.

Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment

Wattmo C, Wallin AK, Londos E, Minthon L.

Gerontologist. 2011 Feb;51(1):17-27. doi: 10.1093/geront/gnq050. Epub 2010 Jun 20.

Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD

Silverman DH, Geist CL, Kenna HA, Williams K, Wroolie T, Powers B, Brooks J, Rasgon NL.

Psychoneuroendocrinology. 2011 May;36(4):502-13. doi: 10.1016/j.psyneuen.2010.08.002. Epub 2010 Sep 1.

A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease

Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K.

Int J Geriatr Psychiatry. 2011 Sep;26(9):937-43. doi: 10.1002/gps.2630. Epub 2010 Dec 28.

Biomarkers for Alzheimer's disease therapeutic trials

Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group.

Prog Neurobiol. 2011 Dec;95(4):579-93. doi: 10.1016/j.pneurobio.2010.11.005. Epub 2010 Dec 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias